IN2014MU00212A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00212A
IN2014MU00212A IN212MU2014A IN2014MU00212A IN 2014MU00212 A IN2014MU00212 A IN 2014MU00212A IN 212MU2014 A IN212MU2014 A IN 212MU2014A IN 2014MU00212 A IN2014MU00212 A IN 2014MU00212A
Authority
IN
India
Prior art keywords
free base
amorphous form
sitagliptin free
sitagliptin
provides
Prior art date
Application number
Inventor
Shri Prakash Dhar Dwivedi
Brij Khera
Kumar Kamlesh Singh
Kirtipalsinh Sajjansinh Solanki
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2015/000035 priority Critical patent/WO2015114657A2/en
Priority to IN212MU2014 priority patent/IN2014MU00212A/en
Publication of IN2014MU00212A publication Critical patent/IN2014MU00212A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

AMORPHOUS FORM OF SITAGLIPTIN FREE BASE The present invention provides an amorphous form of sitagliptin free base of Formula (I). The invention further provides a process for preparation of an amorphous form of sitagliptin free base. The process comprises a) providing a solution or suspension of sitagliptin free base in one or more solvents; and b) obtaining the amorphous form of sitagliptin free base by the removal of the solvent. (I)
IN212MU2014 2014-01-21 2015-01-21 IN2014MU00212A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2015/000035 WO2015114657A2 (en) 2014-01-21 2015-01-21 Amorphous form of sitagliptin free base
IN212MU2014 IN2014MU00212A (en) 2014-01-21 2015-01-21

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN212MU2014 IN2014MU00212A (en) 2014-01-21 2015-01-21

Publications (1)

Publication Number Publication Date
IN2014MU00212A true IN2014MU00212A (en) 2015-08-28

Family

ID=53059374

Family Applications (1)

Application Number Title Priority Date Filing Date
IN212MU2014 IN2014MU00212A (en) 2014-01-21 2015-01-21

Country Status (2)

Country Link
IN (1) IN2014MU00212A (en)
WO (1) WO2015114657A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016016260A (en) 2016-12-08 2018-06-07 Alparis Sa De Cv New solid forms of sitagliptin.
CN109580833B (en) * 2018-12-31 2021-12-03 辰欣药业股份有限公司 Method for determining enantiomer impurities in sitagliptin raw material and preparation
KR20210057603A (en) 2019-11-12 2021-05-21 제이투에이치바이오텍 (주) Process for preparing sitagliptin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2004085661A2 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP2007504230A (en) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド A novel crystalline form of phosphate of dipeptidyl peptidase-IV inhibitor
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2007035198A2 (en) 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2009084024A2 (en) 2007-11-02 2009-07-09 Glenmark Generics Limited A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
US20090221595A1 (en) * 2007-11-26 2009-09-03 Nurit Perlman Crystalline form of sitagliptin
TW201000485A (en) 2008-03-25 2010-01-01 Teva Pharma Crystalline forms of sitagliptin phosphate
EP2318411A2 (en) 2008-07-03 2011-05-11 Ratiopharm GmbH Crystalline salts of sitagliptin
WO2010122578A2 (en) 2009-04-20 2010-10-28 Msn Laboratories Limited Process for the preparation of sitagliptin and its intermediates
WO2010131025A1 (en) * 2009-05-11 2010-11-18 Generics [Uk] Limited Sitagliptin synthesis
CA2771011A1 (en) 2009-08-13 2011-02-17 Sandoz Ag Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine
KR101222679B1 (en) * 2009-10-21 2013-01-16 한미사이언스 주식회사 Method of preparing sitagliptin and intermediates used therein
EP2407469A1 (en) 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
WO2012076973A2 (en) 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor
EA029539B8 (en) * 2011-03-29 2018-06-29 Крка, Товарна Здравил, Д.Д., Ново Место Pharmaceutical composition of sitagliptin
WO2013001514A1 (en) 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation

Also Published As

Publication number Publication date
WO2015114657A2 (en) 2015-08-06
WO2015114657A3 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
EP3259692A4 (en) Reuse of extracted layout-dependent effects for circuit design using circuit stencils
EP3693366B8 (en) Processes for preparing ask1 inhibitors
SI3433285T1 (en) An improved process for the preparation of sugammadex
NZ765780A (en) 2-(morpholin-4-yl)-1,7-naphthyridines
EA201992183A3 (en) SYNTHESIS OF POLYCYCLIC CARBAMOILYPYRIDONE COMPOUNDS
IL284690A (en) Process for preparing btk inhibitors
EP3166931A4 (en) An improved process for the preparation of enzalutamide
IL260465B (en) Process for the preparation of an antibody-rifamycin conjugate
PL2962675T3 (en) Operation table base for an operation table
PT3233043T (en) Process for preparing hydrogels
BR112017002662A2 (en) process for preparing furfural and / or furfural derivatives.
SG10201501104QA (en) Universal process carrier for substrates
TW201613953A (en) Process for the preparation of cyclic depsipeptides
MX2016017124A (en) Process for the preparation of 3-hydroxypicolinic acids.
IN2014MU00212A (en)
SI3565552T1 (en) An improved process for the preparation of rivaroxaban involving novel intermediate
MX2016015624A (en) Process for preparing thiazole derivatives.
MX2016009325A (en) Method for preparing 1-alkyl-3-difluoromethyl-5-fluor-1h-pyrazole -4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluor-1h-pyrazole -4-carboxylates.
EP3444253A4 (en) Process for preparing ad-35
PL3228619T3 (en) Process for the preparation of apixaban
EA201691203A1 (en) SOLID FORMS OF TENOFOVIRA
MX2016016398A (en) Preparation of piperidine-4-carbothioamide.
MX2016015623A (en) Process for preparing dihydroisoxazole derivatives.
HUP1400378A2 (en) Process for the preparation of apixaban
IN2013MU01501A (en)